Validation of Lung EpiCheck, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals

Conclusions Lung EpiCheck demonstrated strong performance in lung cancer prediction in case–control European and Chinese samples, detecting high proportions of early-stage NSCLC and SCLC and significantly improving predictive accuracy when added to established risk factors. Prospective studies are required to confirm these findings. Utilising such a simple and inexpensive blood test has the potential to improve compliance and broaden access to screening for at-risk populations.

http://erj.ersjournals.com/cgi/content/short/57/1/2002682?rss=1

Source: European Respiratory Journal - January 14, 2021 Category: Respiratory Medicine Authors: Gaga, M., Chorostowska-Wynimko, J., Horvath, I., Tammemagi, M. C., Shitrit, D., Eisenberg, V. H., Liang, H., Stav, D., Levy Faber, D., Jansen, M., Raviv, Y., Panagoulias, V., Rudzinski, P., Izbicki, G., Ronen, O., Goldhaber, A., Moalem, R., Arber, N., Haa Tags: Lung cancer Original Articles: Lung cancer Source Type: research